Understanding the expression patterns of TROP2, prognostic relevance, and therapeutic innovations offers avenues for better-targeted therapies, optimizing therapeutic response, and enhancing breast cancer patient outcomes (18, 21, 22). The gene discussed is TACSTD2; the disease is breast carcinoma.